StemCell Institute Inc. Fundamental Analysis (JPX: 7096.T)
StemCell Institute Inc. (JPX: 7096.T) shows weak financial fundamentals with a PE ratio of 52.99, profit margin of 5.18%, and ROE of 5.50%. The company generates $2.8B in annual revenue with moderate year-over-year growth of 4.93%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 37.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 7096.T's fundamental strength across five key dimensions:
Efficiency Score
Weak7096.T struggles to generate sufficient returns from assets.
Valuation Score
Moderate7096.T shows balanced valuation metrics.
Growth Score
Weak7096.T faces weak or negative growth trends.
Financial Health Score
Excellent7096.T maintains a strong and stable balance sheet.
Profitability Score
Weak7096.T struggles to sustain strong margins.
Key Financial Metrics
Is 7096.T Expensive or Cheap?
P/E Ratio
7096.T trades at 52.99 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 7096.T's PEG of -1.31 indicates potential undervaluation.
Price to Book
The market values StemCell Institute Inc. at 2.86 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 28.47 times EBITDA. This signals the market has high growth expectations.
How Well Does 7096.T Make Money?
Net Profit Margin
For every $100 in sales, StemCell Institute Inc. keeps $5.18 as profit after all expenses.
Operating Margin
Core operations generate 6.30 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $5.50 in profit for every $100 of shareholder equity.
ROA
StemCell Institute Inc. generates $1.72 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
StemCell Institute Inc. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
StemCell Institute Inc. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
7096.T converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
52.99
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.31
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.86
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.74
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.23
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.17
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.06
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.05
vs 25 benchmark
How 7096.T Stacks Against Its Sector Peers
| Metric | 7096.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 52.99 | 32.14 | Worse (Expensive) |
| ROE | 5.50% | 550.00% | Weak |
| Net Margin | 5.18% | 30133.00% | Weak |
| Debt/Equity | 0.23 | 0.56 | Strong (Low Leverage) |
| Current Ratio | 1.17 | 5.70 | Neutral |
| ROA | 1.72% | 3.00% | Weak |
7096.T outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews StemCell Institute Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
92.25%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
140.96%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-70.35%
Industry Style: Defensive, Growth, Innovation
Declining